Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 11, 2023 Category: Research Source Type: clinical trials
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
Condition: de Novo Heart Failure Intervention: Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials
Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.
Conditions: Heart Failure; Ventricular Remodeling; Ventricular Dysfunction Intervention: Drug: SGLT2 inhibitor Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2023 Category: Research Source Type: clinical trials
